Innoviva (INVA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.56
- Estimate
- $0.50
- Surprise
- +11.5%
- Revenue (period 2026-06-30)
- $119.6M
- Score at report (before → after)
- 6.5 → 6.5/10
Revenue source: xbrl.
How the report landed
Innoviva (INVA) beat the $0.50 estimate with adjusted EPS of $0.56 — a large 11.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Hold at 6.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates INVA Buy (Wait) at 5.6/10.
3 of the last 4 quarters beat the estimate; this quarter's +11.5% surprise compares with a -92.9% four-quarter average. Next scheduled report: 2027-02-24.
What supports the rating
- Strong earnings beat streak (3/4)
- High-quality business
What argues against it
- Weak growth
- Negative momentum
- Momentum 1.8 < 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.49
- Entry target
- $17.66
- Price target
- $30.28
- Stop
- $16.42
- Upside to target
- +63.8%
- Reward-to-risk
- 7.8:1
At 8.1× trailing and 8.6× forward earnings, consensus estimates imply little change in earnings power.
Risk check: RSI 22 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
INVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.35B
- P/E (fwd)
- 8.6
- P/E (ttm)
- 8.1
- 52-week range
- $18.66–$25.15
- Off 52-week high
- 26.5%
- RSI (14)
- 22
- Volume vs avg
- 0.93×
- Score today
- 5.6/10